New Launch1 Apr 2025, 02:28 pm
Glenmark Pharmaceuticals Inc., USA Launches Vancomycin Hydrochloride for Injection USP
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481. The Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $39.3 million as per IQVIA™ sales data for the 12-month period ending January 2025.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial).
- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories Limited, NDA 209481.
- The Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $39.3 million as per IQVIA™ sales data for the 12-month period ending January 2025.